Pfizer to Present Data From 57 Abstracts at IDWeek 2026 Including Next-Generation Pneumococcal Vaccine Results

Pfizer will showcase data from 57 company-sponsored, investigator-sponsored, and collaborative research abstracts at IDWeek 2026, a major infectious disease congress running October 21-24 in Washington, D.C. The presentations span 12 oral sessions and cover Pfizer's vaccines and anti-infective therapies across its infectious disease pipeline and portfolio.

A late-breaking highlight will feature immunogenicity, safety, and tolerability data from a Phase 2 study comparing Pfizer's 25-valent pneumococcal conjugate vaccine candidate (PF-07872412) with its already-approved PREVNAR 20 in healthy infants. Topline data from that study were first disclosed in May 2026, and the IDWeek presentation represents the first full clinical readout. The data are expected to support the candidate's ongoing pediatric Phase 3 program. Additional presentations will cover real-world and clinical data on RSV and Lyme disease, including results from Pfizer's registrational Lyme vaccine candidate.

Separately, a CNBC Fast Money segment named Pfizer as a final trade pick on October 14, and several Yahoo Finance comparisons weighed Pfizer against other high-yield dividend stocks including Healthpeak, Clorox, and British American Tobacco, reflecting continued investor interest in the stock's income profile amid its pipeline activity.